Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Although the FDA has since removed these drugs from its shortage list, stakeholders say compounded drugs continue to be sold.

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes ...

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

The Pharmacy and Poisons Board (PPB) has issued a second warning against the unregulated use of Ozempic for weight loss. This ...

CHARLOTTE — Novo Nordisk announced Monday that people who use Ozempic can now get it for half the price if you pay in cash.

Recent federal and state developments have shifted the ground under medispas. The US Food and Drug Administration (FDA) ...

The Ministry of Health, through the Pharmacy and Poisons Board (PPB), has issued a cautionary advisory to members of the ...

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...